title: The novel small molecule α9α10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic.
abstract: Chronic pain is inadequately managed with currently available classes of analgesic drugs. Recently, peptide antagonists of the α9α10 nicotinic acetylcholine receptor were shown to be analgesic. The present study was conducted to characterize a novel small molecule, non-peptide antagonist at nicotinic receptors. The tetrakis-quaternary ammonium compound ZZ-204G was evaluated for functional activity on cloned nicotinic receptors expressed in Xenopus oocytes. In-vivo efficacy was assessed in rat models of tonic inflammatory pain (formalin test), neuropathic pain (chronic constriction nerve injury), and thermal nociception (tail flick test). ZZ-204G was an antagonist at nicotinic receptors inhibiting the α9α10 subtype with an IC₅₀ of 0.51 (0.35-0.72) nM. Antagonist activity at other nicotinic subtypes (α1β1δε, α2β2, α2β4, α3β2, α3β4, α4β2, α4β4, α6/α3β2β3, α6/α3β4 and α7) was 10-1000-fold lower than at the α9α10 subtype. In competition binding assays, the k(i) of ZZ-204G at γ-aminobutyric acid(A), serotonin(3), γ-aminobutyric acid(B), κ- and μ-opioid receptors was 1000- to >10,000-fold lower than at α9α10 nicotinic receptors. Parenteral administration of ZZ-204G dose-dependently decreased nociceptive behaviors (paw flinches) in the formalin test and mechanical hyperalgesia in the chronic constriction nerve injury model of neuropathic pain. ZZ-204G was not antinociceptive in the tail flick assay. Results from the rotarod assay indicated that lower doses of ZZ-204G that were analgesic did not alter motor function. In summary, ZZ-204G represents a prototype small molecule antagonist for α9α10 nicotinic receptors and provides a novel molecular scaffold for analgesic agents with the potential to treat chronic inflammatory or neuropathic pain.
authors.affiliation: Department of Anesthesiology, Loyola School of Medicine, Maywood, IL, USA.
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Holtman
authors.forename: Linda P
authors.initials: LP
authors.lastname: Dwoskin
authors.forename: Cheryl
authors.initials: C
authors.lastname: Dowell
authors.forename: Elzbieta P
authors.initials: EP
authors.lastname: Wala
authors.forename: Zhenfa
authors.initials: Z
authors.lastname: Zhang
authors.forename: Peter A
authors.initials: PA
authors.lastname: Crooks
authors.forename: J Michael
authors.initials: JM
authors.lastname: McIntosh
mesh_terms: D000480:Alkynes / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D000700:Analgesics / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001554:Benzene / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D003251:Constriction, Pathologic / Q000150:complications; D005240:Feasibility Studies; D005557:Formaldehyde / Q000009:adverse effects; D006930:Hyperalgesia / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D009043:Motor Activity / Q000187:drug effects; D009437:Neuralgia / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D018733:Nicotinic Antagonists / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D021122:Protein Subunits / Q000037:antagonists & inhibitors; D011726:Pyridinium Compounds / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011978:Receptors, Nicotinic / Q000378:metabolism*
chemical_list: C570285:5,5',5',5'-(1,2,4,5-benzenetetrayl)tetrakis-(1-(3-phenylpyridinium)-4-pentyne); D000480:Alkynes; D000700:Analgesics; D018733:Nicotinic Antagonists; D021122:Protein Subunits; D011726:Pyridinium Compounds; D011978:Receptors, Nicotinic; D005557:Formaldehyde; D001554:Benzene